Literature DB >> 20334955

Telomerase mRNA expression and immunohistochemical detection as a biomarker of malignant transformation in patients with inflammatory bowel disease.

Victoria Gonzalo1, Anna Petit, Sergi Castellví-Bel, Maria Pellisé, Jenifer Muñoz, Carme Piñol, Francisco Rodríguez-Moranta, Joan Clofent, Francesc Balaguer, M Dolores Giráldez, Teresa Ocaña, Anna Serradesanferm, Jaume Grau, Josep M Reñé, Julián Panés, Antoni Castells.   

Abstract

BACKGROUND: Inflammatory bowel disease is a premalignant condition for developing colorectal cancer. Since a correlation has been suggested between telomere length, chromosomal instability and neoplastic transformation in this setting, we sought to investigate whether telomerase expression in colorectal mucosa may constitute a biomarker for malignant transformation in patients with inflammatory bowel disease. PATIENTS AND METHODS: Forty-seven patients with inflammatory bowel disease with and without cancer or dysplasia were evaluated for human telomerase reverse transcriptase hTERT immunostaining in paraffin-embedded, formalin-fixed colorectal tissues. In addition, hTERT mRNA expression was assessed in fresh frozen specimens from a second set of 35 patients with inflammatory bowel disease at high or low risk for neoplastic transformation.
RESULTS: Five out of 10 patients (50%) with colorectal cancer or high-grade dysplasia exhibited hTERT immunochemical detection in adjacent, non-transformed colonic mucosa. However, this phenomenon was also observed in non-affected mucosa of patients with either long-standing (13 out of 19 patients; 68%) or short duration (13 out of 18 patients; 72%) disease without cancer or dysplasia. On the other hand, hTERT mRNA expression in non-affected colorectal mucosa from patients at high risk for neoplastic transformation due to long-standing disease was higher than in those at low risk (7.42+/-6.43 vs. 2.87+/-1.47, respectively; p=0.006).
CONCLUSIONS: Whereas hTERT immunostaining provides equivocal results, the observation that patients at high risk for colorectal cancer because of long-standing inflammatory bowel disease overexpress hTERT mRNA in non-affected colorectal mucosa suggests its potential usefulness as a biomarker of the risk of malignant transformation. Copyright 2009 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20334955     DOI: 10.1016/j.gastrohep.2009.12.011

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  3 in total

1.  Differences in telomerase activity between colon and rectal cancer.

Authors:  Georgios D Ayiomamitis; George Notas; Apostolos Zaravinos; Adamantia Zizi-Sermpetzoglou; Maria Georgiadou; Ourania Sfakianaki; Elias Kouroumallis
Journal:  Can J Surg       Date:  2014-06       Impact factor: 2.089

2.  The prognostic value of hTERT expression levels in advanced-stage colorectal cancer patients: a comparison between tissue and serum expression.

Authors:  María José Safont; Mireia Gil; Rafael Sirera; Eloísa Jantus-Lewintre; Elena Sanmartín; Sandra Gallach; Cristina Caballero; Nieves Del Pozo; Eugenio Palomares; Carlos Camps
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

3.  Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs.

Authors:  Yoko Matsuda; Taro Yamashita; Juanjuan Ye; Mami Yasukawa; Keiko Yamakawa; Yuri Mukai; Mitsuhiro Machitani; Yataro Daigo; Yohei Miyagi; Tomoyuki Yokose; Takashi Oshima; Hiroyuki Ito; Soichiro Morinaga; Takeshi Kishida; Toshinari Minamoto; Shinji Yamada; Junko Takei; Mika K Kaneko; Motohiro Kojima; Shuichi Kaneko; Tsutomu Masaki; Masahiro Hirata; Reiji Haba; Keiichi Kontani; Nobuhiro Kanaji; Nobuyuki Miyatake; Keiichi Okano; Yukinari Kato; Kenkichi Masutomi
Journal:  J Pathol       Date:  2022-03-23       Impact factor: 9.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.